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ABSTRACT
The authors examked the affinies of 36 typloal and atyploal
antipsychotic agents for the cloned rat 5-hydroxytryptamine-6
(5-HT) and rat 5-hydroxytryptamine-7 (5-HT) receptors in fran-
slently expressed COS-7 cells(5-HT1) or stably tranSfeCted HEK-
293 cells (5-H-r. receptors). Clozapine and several related atyp-
Ical antipsychotic agents (rilapine, olanzeplne, tiospirone, fluper-
lapine, clorotepine and zotepe) had high affinities for the newly
discovered 5-H receptor (K,s < 20 nM). The 5-HT7 receptor
bound clozapine, rilapine, fluperlapine, clorotepine, zotepine and
lispelidone but not t1os*one and olanzeplne, with affinies less
than 15 nM. In addon, several typical antipsychotic agents
(chiorprothixene, chlorpromazine, clothiapine and fluphenazine)
had high affinides for both the 5-HT5 and 5-HT7 receptors.
Pimozide, a dipheny1but1ppeddine, had the highest affinity of all
the typical antipsychotic agents tested for the 5-HT1 receptor (K,
= 0.5 nM). Three putative atypkal antipsychotic agents melpe-
rone, amperozkie and MDL 100907 did not bind with high
affinities to either the 5-HT or 5-HT receptors (K,s > 50 nM).
Several dopamine-selecveantipsychotic agents(radoprkie, rim-
cazole and penfluridoO had essentlelty no affinity for either the 5-
HT8 or 5-HT7 receptors (K values > 5000 nM). Although 5-HT6
or 5-HT receptor affinity alone does not prediCt whether or not
a drug will have atypical antipsychoc actMty, the relatively high
affinity of the 5-HT receptor for several clozapine-related corn-
pounds, In comblnatlon with the enrichment of 5-HT6 messenger
RNA in the stilatum, suggests that the ability of at least some
atypical antipsychotic drugs to interact with 5-HT5 receptors may
contribute to their lack of extrapyramidal side effects.
Clozapine, the prototypical atypical antipsychotic drug, has
greater efficacy in treatment-resistant schizophrenia than do
typical antipsychotic drugs (Kane et aL, 1988; Meltzer et aL,
1989a). In addition, unlike any other known antipsychotic
agent, clozapine is effective in masking symptoms of tardive
dyskinesia and tardive dystonia without appreciably causing
other types ofextrapyramidal symptoms (Meltzer and Luchins,
1984; Friedman and Lannon, 1989; Meltzer et al., 1989a Lie-
berman et aL, 1991). The mechanism of action of clozapine
remains unknown, although previous reports indicated that
clozapine has functionally important interactions with seroto-
nergic (Fink et aL, 1984; Meltzer et aL 1989b), dopaminergic
(Altar et aL, 1988), muscarinic (Miller and Hilley, 1974) and
alpha-i adrenergic (Cohen and Lipinski, 1986) receptors. More
recent studies examined the binding of clozapine and related
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compounds to the newly cloned D4 receptor (Van Tol et aL,
1991), the 5-HTic receptor (Canton et aL, 1990; Roth et aL,
1992) and all five subtypes of muscarinic receptors (Bolden et
aL, 1992).
Since our previous study of the 5-HT1 binding profile of
clozapine and related atypical antipsychotic agents (Roth et aL,
1992), several additional 5-HT receptors have been cloned,
including the 5-HTp (Kursar et aL, 1992), the 5-HTSA and 5-
HTSB (Matthes et aL, 1993), 5-HT1 and 5-HT1, (Amlaiky et
aL, 1992; McAllister et aL, 1992; Zgombick et aL, 1992; Loven-
berg et aL, 1993), 5-HI’. (Monsma et aL, 1993) and 5-HT7 (Shen
et aL, 1993) receptors. Only the 5-HT. (Monsma et aL, 1993)
and 5-HT7 (Shen et aL, 1993) receptors were reported to bind
clozapine with high affinities; scant published information is
available in regard to the pharmacology of most of these newly
cloned 5-HT receptor subtypes.
The 5-HT6 and 5-HT7 receptors pharmacologically resemble
the 5-HT2 receptor (Monsma et aL, 1993; Shen et aL, 1993),
which has been postulated to be a major site of action of
clozapine and related compounds (Meltzer et aL, 1989b). In
particular, Monama et aL (1993) and Shen et aL (1993) noted
ABBREViATiONS: 5-HT, serotonin; LSD, lysergiC acid diethylamide.
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that both the 5-HT6 and 5-HT7 receptors appeared to have
high affinities for many psychotherapeutic drugs of diverse
classes (e.g., antidepressants and antipsychotics). In addition,
the 5-HT6 receptor messenger RNA is highly enriched in stria-
tum (Monsma et at., 1993), a potentially important site of
action of antipsychotic drugs with regard to both extrapyra-
midal symptoms and perhaps cognitive functioning.
For these reasons, we examined the binding affmities of 36
typical and atypical antipsychotic drugs for the rat 5-HT6 and
5-HT7 receptors by using both transient and stably expressing
cell lines. We discovered that several atypical antipsychotic
agents with high affinities for the 5-HT2 receptor also possessed
high affinities for both the 5-HT6 and 5-HT7 receptors. It is
conceivable that certain unique properties of clozapine and
related compounds could be mediated by functionally important
interactions with either 5-HT6 or 5-HT7 receptors.
Materials and Methods
Materials. The sources of drugs used in this study were previously
specified (Meltzer et aL, 1989b; Roth et aL, 1992) with the exception of
the following compounds: olanzepine (Eli Lilly, Indianapolis, IN), MDL
100907 (Marion Merrell Dow, Cincinnati, OH), clorotepine (-) and
clorotepine (+) (gifts of P. Seaman, Toronto, Canada), N-desmethyl
and N-oxideclozapine metabolites (Sandoz, Basel, Switzerland). [3H]-
LSD (66 Ci/mmol) was from New England Nuclear (Boston, MA). Cell
culture supplies were from GIBCO/BRL (Gaithersburgh, MD), com-
mon laboratory chemical were from Sigma (St. Louis, MO) and molec-
ular biology reagents were obtained from Stratagene (Torry Pines, CA)
or New England BioLabs (Boston, MA).
Cell culture. COS-7 cells were transfected with p5HT7 or pSVK3-
5HT1C by using the DEAE-dextran technique of Culien (Cullen, 1987)
exactly as previously described (Choudhary et aL, 1992, 1993). The
HEK-293 cells that express the 5-HT6 receptor were previously char-
acterized (Monsma et aL, 1993). The GF-6 cells, which stably express
the 5-HT2 complementary DNA, were from D. Julius and were previ-
ously characterized (Choudhary et aL, 1992, 1993). All cells were grown
in Dulbecco’s modified Eagle’s medium, which contained high glucose
(4500 mg/l), supplemented with glutamine, pyruvate and 10% fetal calf
serum (regular medium). For binding experiments, the cells were
switched to regular medium that contained 10% dialyzed medium at
least 48 hr before harvesting.
Radloligand binding. The cells were washed with phosphate-
buffered saline (148 mM NaC1, 2.7 mM KC1, 8 mM NaH2PO4, pH =
7.40, twice for 10 mm each) and then harvested with a cell scraper into
20 ml of phosphate-buffered saline per plate. After concentration by
centrifugation (1000 x g for 10 mm), the cells were lysed in binding
buffer (50 mM Tris Cl, pH = 7.40) and membranes were collected by
centrifugation (20,000 x g for 20 mm at 4#{176}C).After resuspension and
recentrifugation in binding buffer, the membranes were frozen as tight
pellets at -80’C.
The 5-HT2 and 5-HT1c binding assays were performed exactly as
previously described (Roth et al., 1992; Choudhary et aL, 1992). For 5-
NT5 and 5-HT7 receptors, [3HJ-LSD binding assays were performed in
a total volume of 0.2 or 0.5 ml, respectively, at 25’C for 90 mm in the
dark, as previously detailed (Roth et aL, 1991, 1992). After incubation,
the membranes were collected onto polyethyleneimine-pretreated glass
fiber filters (GF/C, Whatman), washed with 5 ml of ice-cold binding
buffer three times and then quantified by liquid scintillation spectro-
photometry. Quenching was corrected for by the sample channels ratio
technique. Nonspecific binding was determined with 10 iM clozapine
and represented at least 95% of total binding. Competition and satu-
ration binding data were analyzed by using the LIGAND program
(Munson and Rodbard, 1980). The data reported here represent the
mean of at least two separate competition binding studies in which five
to seven concentrations of unlabeled ligand were used with duplicate
determinations for each point. The protein concentration was deter-
mined with the Bio-Rad kit (Richmond, CA) by using bovine serum
albumin as the standard.
Data analysis. The pK1 values of typical and putative atypical
antipsychotic drugs were compared by t testa and correlated by using
Spearman rho coefficient. The pK, values were used as described in
Meltzer et a!. (1989b) to determine whether the 5-HT6 and 5-HT7 pK
values contributed to the discrimination of typical and atypical anti-
psychotic drugs by using stepwise discriminative function analysis
(Meltzer et at., 1989b).
Results
Expression of rat 5-fiT6 and 5-HT7 receptors. The
HEK-293 cells that stably expressed the rat 5-HT6 receptor
were prepared as previously detailed (Monsma et cii., 1993). A
Fig. 1. Saturation binding plots of [3H]-LSD to 5-HT6 (A) and 5-HT (B)
receptors. Shown are typical saturation binding isotherms for rHJ-LSD
binding to 5-HT. (A) and 5-HT7 (B) receptors. Shown are total (0),
nonspecIfic (#{149})and specific (0) counts per minute bound at increasing
[3H]-LSD concentrations (in nanomolar quantities). The data were fit by
using the UGAND program; the lines were computer generated. Cloza-
pine (10 M) was used to define nonspecific binding. For the 5-HT6
receptor, the following values were Obtained (means ± S.E.M.): Kd = 1.3
± 0.6 nm; B = 1 .34 ± 0.3 pmol/mg. For the 5-HT7 receptor, the
following values were Obtained (means ± S.E.M.): Kd = 7 ± 2.5 nM; B
= 24.7 ± 4.3 pmol/mg.
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line that expressed high levels of 5-HT6 receptors was chosen
for further study. As shown in figure 1A, [3H]-LSD bound with
high affinity and capacity to 5-HT6 receptors stably expressed
in HEK-293 cells. Untransfected HEK-293 cells do not express
specific [3HJ-LSD binding (not shown). Figure 2 shows the time
course of binding of [3HJ-LSD to the 5-HT6 and 5-HT7 recep-
tors.
For 5-HT7 receptors, transiently transfected COS-7 cells
were used because they expressed higher receptor levels than
did stably transfected HEK-293 cells. As shown in figure 1B,
[3HJ-LSD bound to 5-HT7 receptors transiently expressed in
COS-7 cells. As a control, untransfected COS-7 cells do not
express specific [3HJ-LSD binding (Roth et al, 1992).
Binding of typical antipsychotic drugs to 5-HT6 and
5-HT7 9C9PtO1’8. Figure 3 shows that several typical antipsy-
chotic drugs bound to 5-HT6 receptors with high affinity.
Tables 1 to 3 summarize our findings with 36 typical and
atypical antipsychotic agents. For comparison, pK1 values for
the 5-HT2, 5-HT1 and D2 receptors are also shown (tables 2
and 3). All pK1 values were derived from binding assays per-
formed with cloned receptors unless otherwise specified. As can
be seen, chlorprothixene, chlorpromazine, amoxapine, thiori-
dazine, loxapine, clothiapine, fluphenazine, clorotepine (-) and
perphenazine all had high affinities for the 5-HT6 receptor (K1
< 20 nM). Pimozide, thiothixene, trifluoperazine and aceto-
phenazine had intermediate affinities (K < 100 nM); meson-
dazine, molindone and spiperone had low affinities (K1 < 1100
nM). Halopenidol, tnifluopenidol, metoclopramide, nimcazole,
remoxipnide, raclopnide and penfluridol did not significantly
inhibit 5-HT6 radioligand binding (K1 > 5000 nM).
The affinities of these drugs for the 5-HT7 receptors differed
in several respects. Pimozide (fig. 4, table 1) had the highest
affinity of all the typical antipsychotic drugs tested (K1 = 0.5
nM); acetophenazine, chiorprothixene, fluphenazine, thiothix-
ene and spiperone all had affinities less than 20 nM. Amoxap-
ine, chlorpromazine, clothiapine, loxapine, perphenazine, thion-
idazine, tnifluoperazine and trifluopenidol had intermediate af-
finities (K1s < 150 nM); halopenidol, molindone and
prochiorpenazine had low affinities (K1s < 1000 nM). Rimca-
zole, remoxipnide, naclopnide and penfluridol all had essentially
no affinity for the 5-HT7 receptors (J(s > 5000 nM).
Binding of atypical antipsychotic drugs to 5-HT6 and
5-HT7 receptors. We also evaluated the affinities of many
putative atypical antipsychotic drugs for the cloned 5-HT6 and
5-HT7 receptors. The rationale for considering all the following
compounds, with the exception of clonotepine, atypical was
previously given (Meltzer et aL, 1989b; Roth et al., 1992):
clozapine, fluperlapine, nilapine, penlapine, tiospirone, olanze-
pine, nispenidone, clonotepine (+), zotepine, ampenozide, mel-
perone and tenilapine. Bogeso et at. (1991) suggest that cloro-
tepine (+) behaves atypically, although clonotepine (-) has a
typical profile. For the 5-HT6 receptor, zotepine, clorotepine
(+ and -), clozapine, nilapine, olanzepine, tiospirone and flu-
Fig. 3. Inhibition of [3H]-LSD
binding to 5-HT5 receptors by
various typical and atypical an-
tipsychotic drugs. Shown are
typical competition bEnding iso-
therms for rH]-LSD bound to
5-HT. receptors. The data rep-
resent the mean percent of the
maximum specific bEnding (de-
fined with 10 MM clozapine);
the lines were drawn by the
computer by using parameter
estimates from the LIGAND
program.
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TABLE 1
#{149}IndIngcharactedetics of 5-HI. and 5-HT receptors
Data represent mean ± S.D. of computer-deilved K, values from UGAND program
fern -2to4sepsateexperlments.
Drug 5-HT. K, (pIQ 5-H-ri K, (plQ
TABLE 2
Binding of typical antipsychotic agents to cloned serotonin
-
Shown are pKl values for cloned 5-HT1c, 5-HT2, 5-HT and 5-HT receptors except
as otherde noted.
5-MT5 5-HT7 5HT2 t4lT1c D2
Chlorprothixene 8.5 8.3 9.4 ND” ND
Chlorpromazine 8.4 7.6 8.6 7.6 8.9k’
Amoxapine 8.2 7.4 9.0 8.7 ND
Thioridazine 8.2 7.2 8? 7.1 8.1
Loxapine 7.8 7.4 8.7’ 8.0 8.1
Clothiapine 7.8 8.37 9.1 ND ND
Fluphenazine 7.8 8.1 8.7 6.2 9.3”
Clorotepine (-) 7.8 8.6 ND ND 7.9’
Perphenazine 7.8 7.6 8.6’ 7.3 9.2’
Thiothixene 7.4 7.9 7.3’ 5.8 9.2’
Trifluperazine 7.2 7.1 8.4’ 7.0 9.7”
Pimozide 7.2 9.3 8.1’ <5 8.6”
Acetophenazine 7.1 8.6 ND 6.0 ND
Prochlorperazine 6.8 6.7 8.2’ 7.1 8.3’
Mesoridazone 6.8 7.1 8.2 71 8.1’
Molindone <5.3 6.6 6.3 ND 7.8”
Spiperone 5.8 8.0 9.48 6.01 10.2”
Haloperidol <5.3 6.6 7.8 5.6 9.3”
Trifiuperidol <5.3 7.3 ND ND ND
RcaZOIe <5.3 <5.3 <5.3 ND ND
Raclopride <5.3 <5.3 <5.3 <5.3 8.7”
Penfluridol <5.3 <5.3 7.2 ND ND
Metoclopramide <5.3 ND ND ND ND
67 ± 12 (7.2) 549 ± 120(6.3)
-t Meltzer etal., 1989 (rat cortex, not cloned).
S Malmberg at al., 1993 (cloned, expressed in Ltk- cells).
C Van Tol at a!., 1991 (cloned, expressed in Ltk- cells).
d Not done.
TABLE 3
Binding of atypical antipsychotic agents to cloned
rece
Shown we plc values obtained from cloned 5-HT,,
receptors except as otherwIse noted.
serotonin
5-HT. 5-MT. and t-HT7
pI
Drug 5-HT, 5-1117 5HTIC
5HT2 D2
Clorotepine (+) 9.4 9.4 MY
Zotepine 9.0 8.8 ND
Olanzepine 8.6 7.0 ND
Clozapine 8.4 8.2 8.2
Rilapine 8.2 8.6 7.6
Fluperlapine 7.8 8.3 7.7
Tiospirone 7.6 9.2 8.0
Perlapine 7.2 7.6 ND
Amperozide 7.2 6.3 5.9
Tenilapine 7.0 7.3 7.2
Risperidone 6.4 8.9 7.5
Melperone 5.9 6.3 5.9
ND
9.2’
ND
8.4
9.2
8.2
10.2
7.9’
7.9
7.4
9.6
7.1
8.8”
9.0’
ND
7.25”
74’
6.5’
9.3”
6.3’
6.3”
5.8’
8.8”
6.7’
penlapine all had high affinities; amperozide, perlapine and
tenilapine had intermediate affinities. Rispenidone and melpe-
none had weak affinities; the putative antipsychotic drug MDL
100907 and the pharmacologically inactive metabolite of do-
zapine, clozapine-N-oxide, had no affinity for the 5-HT6 recep-
ton.
For the 5-HT7 receptor, compounds with structures similar
to that of clozapine (fluperlapine and perlapine) had relatively
high affinities, as did nispenidone, zotepine, clorotepine (±) and
tiospirone (tables 1-3). The major metabolite of clozapine, N-
desmethylciozapine, had higher affinity for the 5-HT6 than for
the 5-HT receptor. Interestingly, rispenidone had a 303-fold
Meftzer at a!., 1989 (rat striatum).
“VanToleta/., 1991 (cloned, Ltk- cells).
C Malmberg at a!., 1993 (cloned, Ltk- cells).
d Not done.
higher affinity for the 5-HT7 than for the 5-HI’6 receptor,
olanzepine preferred the 5-HT6 receptor by 40-fold (table 1).
However, most atypical compounds had similar affinities for
both 5-HT6 and 5-HT7 receptors.
The possibility that the relative affinity of atypical antipsy-
chotic drugs for the 5-HT6 and 5-HT7 receptors compared with
the D2 receptor distinguishes these compounds from typical
antipsychotics was also examined because the previously re-
ported 5-HT2/D2 ratio was a sensitive index of atypicality
(Meltzer et aL, 1989b). To do this, pK1 values were used (tables
1406 Roth etal. Vol. 268
Phenothiezkes
cNone #{231}T)’
Thioridazine (1)
RuphenazW* (1)
Perphenealne (1)
Trifluoperazine (1)
Acetophenealne (1)
Prochkne if)
Mesoridazine (1)
Thioxanthenes
Chiorprothixene (1)
Thiothixene if)
Heterocydic Compounds
Zotepine (A?
clorotepine (+) (A)
corot (-) (1)
Clozapine (A)
Amoxapine m
Lox#{231}r)
aothiepine Cr)
Fluperlapine (A)
Pedapine (A)
Melperone (A)
Spiperor*(!)
TrIfIUOrperIdOI (1)
Haloperidol (1)
Diphenylbutylpiperidine
Plmozide (1)
Penfluridol (r)
Dlphenylbutylplperazine
Amperozide (A)
Miscelaneous Compounds
Olanzeplne (A)
Rilapine (A)
N-DesmethylclOZapine
(I)
Tiospirone (A)
Risperidone (A)
MDL 100907 (A)
Rimcazole Cr)
Raclopride Cr)
Remoxipride
Molindone Cr)
Metoclopramide
Clozaplne-N-oxide (l
Colorpromazine-N-
Oxide (I)
TypIcaI.
C lnave.
d  done.
4 ± I .4(8.35)
6.6 ± 1.7(8.18)
17 ±3.3(7.77)
17 ± 2.9 (7.77)
66±48(7.18)
72 ± 48 (7.14)
148±92(6.83)
159±53(6.8)
3 ± 0.6(8.52)
45 ±2.2(7.35)
1.17 ± 0.4(8.93)
0.41 ±0.2(9.38)
17.7 ±5(7.75)
4 ±0.7(8.40)
6±0.6(8.22)
15± 1.5(7.82)
16±6(7.80)
16.5±10(7.78)
70 ± 21 (7.15)
1254 ± 359(5.9)
1595 ± 842(5.80)
>5000 (<5.3)
>5000 (<5.3)
71 ±30(7.15)
>5000 (<5.3)
2.5 ± 0.9 (8.6)
6.95 ±38(8.2)
9.4 ±7(8.02)
74 ± 52 (7.13)
425 ± 59(6.37)
>5000
>5000
>5000
>5000
>5000
>5000
>5000
>5000
>5000
21 ± 7(7.6)
70 ± 48 (7.15)
8± 5 (8.1)
23 ± 7(7.6)
80± 13 (7.1)
2.4 ± I (8.62)
196±80(6.7)
73 ± 40 (7.14)
5.6 ± 1 (8.25)
12±1(7.9)
1.78 ± 0.6 (8.75)
0.38±0.05(9.42)
1 .3 ± 0.41 (8.89)
6.3 ± 3.7(8.2)
40.6±25(7.39)
43±25(7.37)
4.3±2.6(8.37)
4.6 ± 2(8.34)
28 ± 3(7.55)
578 ± 135(6.24)
9.9 ± 5.7(8.00)
63 ± 31 (7.2)
263 ± 41 (6.58)
0.5 ± 0.05(9.3)
>5000 (<5.3)
104 ± 12(6.98)
2.8± 1.7(8.6)
14.9(7.8)
0.64 ± 0.06(9.19)
1.39 ± 1 (8.86)
ND”
>5000
>5000
>5000
>5000
265 ± 36(6.6)
ND
>5000
>5000
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Fig. 4. InhibitIon of rHJ-LSD
binding to 5-HT7 receptors by
various typical and atypical an-
tipsychotic drugs. Shown are
typicel competition birdng iso-
therms for [HJ-LSD bound to
5-HT7 5CtOIS. The data rep-
resent the mean percent of
maximum specific blidng (de-
fined with 10 MM clozapkie);
the knes were drawn by the
computer by using parameter
estimates from the UGAND
program.
2 and 3). The differences in the pK, values for the 5-HT8 and
D2, for the 5-HT7 and D2 and for 5-NT2 and D2 receptors were
significantly greater for atypical than typical antipsychotic
drugs (P < .001, data not shown). Stepwise discniminant func-
tion revealed that the plC., values for the D2 receptor contnib-
uted most to the discrimination, followed by the 5-HT2 (average
squared canonical correlation with D2 alone = 0.61; with 5-
NT2 8ddd, 0.71). The stepwise discrimination did not find
significant improvement in the prediction by adding 5-HT6 or
5-HT7 K1 values.
Discussion
The major finding of this article was that a large number of
both typical and atypical antipsychotic drugs have high affini-
ties for the cloned rat 5-HT and 5-HT7 receptors. Clozapine
and fluperlapine, both of which have been shown clinically to
function as atypical antipsychotic agents (Korsgaard et aL,
1984; Woggon et aL, 1984; Woggon et aL, 1986; Kane et aL,
1988), had high affinities for both 5-HT6 and 5-HT7 receptors.
These results suggest that a functional interaction with 5-HT8
and/or 5-HT7 receptors may contribute to the unique effects of
some, but not all, atypical antipsychotic drugs. However, the
ability of drugs to bind to 5-HT and/or 5-HT7 receptors does
not appear to be essential for producing an antipsychotic drug
that has little adverse effect on extrapyramidal function, e.g.,
melperone.
Previous studies demonstrated that atypical antipsychotic
drugs bind to a large number of neurotransmitter receptors,
including dopaminergic (Meltzer et aL, 1989b), adrenergic
(Cohen and Lipinaki, 1986), cholinergic (Bolden et aL, 1992)
and serotonergic receptors (Meltzer and Nash, 1991). Studies
of the importance of 5-HT receptors for an atypical antipsy-
chotic profile have concentrated on the 5-HT2 receptor and, to
a lesser extent, the 5-HT1c (Roth et aL,1992) and 5-HI’3 and 5-
MT4 receptors (Meltzer and Nash, 1991). Thus, Meltzer et aL
(1989b) demonstrated that atypical antipsychotic drugs, as a
group, have a ratio of 5-HT/D2 K1 values greater than 10;
typical antipsychotic drugs have 5-HT/D2 K1 values less than
10. Since those studies were published, 13 5-HT receptor sub-
types have been clone& 5-HT (Kobilka et aL, 1987), 5-HT,,
(Hamblin and Metcalf, 1991), 5-HTm’ (Voight et aL, 1991), 5-
HT1 (Julius et aL, 1988), 5-HT1,, and 5-HT (Amlaiky et aL,
1992; McAffister et aL, 1992; Zgombick et aL, 1992; Lovenberg
et aL, 1993), 5-HT2 (Pnitchett et aL, 1988), 5-HT, (Kursar et
aL, 1992), 5-HT3 (Maricq et aL, 1991), 5-HTM and 5-HTSB
(Matthes et aL, 1993), 5-HT8 (Monsma et aL, 1993) and 5-HT7
(Shen et aL, 1993). The present studies represent an extension
of our prior studies. Previously, we examined the 5-HT1 recep-
ton and found that the spectrum of drug binding did not favor
a hypothesis that implicated the 5-HT1 receptor in antipsy-
chotic drug actions (Roth et aL, 1991). We now find that most,
but not all, atypical antipsychotic drugs, and selected typical
antipsychotic drugs, bind strongly to 5-HT6 and 5-HT7 recep-
tons.
Monsma et aL (1993) reported the cloning and preliminary
pharmacological characterization ofthe 5-HT6 receptors. These
authors found that many psychoactive compounds with tnicy-
dc and/or heterocycic structures had high affinities for the 5-
HT6 receptor. Interestingly, these authors reported that the 5-
HT. receptor was highly enriched in stniatum and certain limbic
regions. Our results suggest that many atypical antipsychotic
drugs can bind with high affinity to the 5-HT6 receptor. Al-
though we do not know the physiological relevance ofthis high-
affinity binding, it is conceivable that the lack of extrapyra-
midal side effects of clozapine and related compounds could be
the result in part of an action at 5-HT6 receptors in the
striatum. In this regard, it is interesting to note that rispeni-
done, which does not have high affinity for the 5-HI’6 receptor,
can cause extrapyramidal side effects in humans at high doses
(Chouinard et aL, 1993). Consistent with this, thioridazine,
which does not cause catalepsy and appears to have other
atypical features in rats (Merchant and Dorsa, 1993), has a
relatively high affinity for the 5-HI’6 receptor.
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Shen et aL (1993) cloned another 5-HT receptor that they
named 5-HT7. As we report here, the 5-HT7 receptor has high
affinity for pimozide (table 1). Pimozide is a somewhat novel
antipsychotic agent that is effective in the treatment of Tour-
ette’s syndrome, certain cases of obsessive-compulsive disorder
and tics (Cohen et aL, 1992). It is conceivable that some of the
unique actions of pimozide are dependent in part on an action
at the 5-HT7 receptor.
We found no mean differences between the pK1 values of
typical and atypical antipsychotic drugs for 5-HT6 and 5-HT7
receptors (not shown). This result was similar to our previous
finding with regard to the 5-HT2 receptor (Meltzer et aL,
1989b). There was also no clear pattern of greater affinity for
the 5-HT6 or 5-HT7 receptors for either class of drugs. Because
we reported that the ratio of the JC values for 5-HT2 and D2
receptor binding significantly differentiated atypical and typi-
cal antipsychotic drugs (Meltzer et aL, 1989b), a similar ap-
proach was tried by using 5-HT6 and 5-HT7 ratios. We found
no contribution for the 5-HTe and 5-HT7 receptors for the
group as a whole. However, this analysis does not rule out the
possibility that, for specific drugs in which the 5-HT6 or 5-HT7
affinities are high, occupancy of 5-HT6 or 5-HT7 receptors
could contribute to certain therapeutic actions. It is interesting
that the affinities for all drugs for the 5-HT2 receptor, with the
exception of thiothixene and clozapine, was equal to or greater
than that for the 5-HT6 and 5-HT7 receptors.
One of the difficulties with a mere statistical analysis of the
findings by a stepwise discniminant function analysis is that
only one aspect of an atypical antipsychotic drug’s actions is
considered (i.e., lack of extrapyramidal side effects). Clozapine,
which is the prototypic atypical antipsychotic drug, has unique
actions, which include its effectiveness in treatment-resistant
schizophrenia, its apparent lack of induction of tardive dyski-
nesia and its ability to suppress symptoms oftardive dyskinesia
(Kane et aL, 1988; Lieberman et aL, 1991; Meltzer and Luchins,
1984). No currently available antipsychotic drug has these
unique actions, although it is important to remember that none
of the drugs listed as atypical antipsychotics has been used in
large-scale trials for treatment-resistant schizophrenia or tar-
dive dyskinesia. At the present time, we do not know if cloza-
pine’s high affinities for the 5-HT6 and/or 5-HT7 receptors is
essential for its unique actions. When more clinical information
is available on the effectiveness of the drugs listed in table 2,
we may be better able to rule in or out a role for the 5-HT6 and
5-HT7 receptors for the actions of clozapine and similar com-
pounds
In terms of structure-activity relationships (fig. 5), we are
able to reach several conclusions in regard to the tnicycic and
heterocycic molecules and their ability to recognize 5-HT6
receptors. For phenothiazines, an aldehyde in the R2 position
greatly decreased affinity for the 5-HT6 receptor. The nature
of the Ri substituent had little effect with the derivatives
tested, except in the case of chlorpromazine N-oxide, which
was devoid of affinity for the 5-HT6 and 5-HT7 receptors. For
the 5-HT7 receptors, in general, the bulkier the substitution at
the R2 position is, the higher the affinity is; this was particu-
larly clear with acetophenazine > fluphenazine > perphenazine
and tnifluoperazine > prochiorperazine. Similar to the 5-HT6
receptor, the nature of the R2 substituent had little effect on
binding affinity with the exception again, of chlorpromazine
N-oxide.
For heterocydic molecules, a halogen at either the R2 or R3
position was associated with high affinity. This is most clearly
seen by comparing flupenlapine and perlapine. This relation-
ship did not hold consistently with the 5-HT7 receptors, in
which, for instance, loxapine and amoxapine both had lower
affinities than did perlapine. The nature of the R4 substituent
had apparently little effect on the affinities for both the 5-HT6
and 5-HT receptors. Also, the presence of a nitrogen, carbon,
oxygen or sulfur at the Ri position had no detectible effect on
the affinity for the 5-HT5 receptor (compare loxapine and
clothiapine). For the 5-HT7 receptor, however, an oxygen at
the Ri position was generally associated with lower affinity
than was a sulfur (compare clothiapine and loxapine). Demeth-
ylation of the ring nitrogen at R4 had no large effect on the
affinity for either the 5-HT5 or 5-HT7 receptors.
In general, butyrophenones had low affinities for the 5-HT6
receptor. For the 5-HT7 receptor, the nature of the substituent
had great effects on the affinity. In general, the larger the group
is, the higher the apparent affinity is. Thus, for the butyro-
phenone series, we found the following relationship for the 5-
HT7 receptor: spiperone > trifluopenidol > haloperidol > mel-
perone. The presence of nitrogens greatly increased the affinity
for the 5-HT7 receptor; this was seen for both the butyrophen-
ones and the diphenylbutypipenidines. Taken together, these
findings demonstrate that the 5-HI’6 and 5-HT7 receptors,
although they both have a high affinity for many antipsychotic
agents, have distinct structure-activity relationships. These
differences suggest that 5-HT6 and/or 5-HT7-subtype selective
agents could be synthesized.
In conclusion, we discovered that two recently cloned 5-HT
receptors, 5-HT6 and 5-HT7, possessed high affinities for do-
zapine and related atypical antipsychotic agents. The high
affinity of selected typical and atypical antipsychotic agents for
these newly cloned 5-HT receptors may be important for medi-
ating the unique actions of certain antipsychotic drugs. In
particular, the high affinity for the 5-HI’6 receptor, in view of
its concentration in the striatum, suggests that 5-HT6-active
agents could be important for certain motor effects of typical
and atypical antipsychotic agents. The availability of 5-HT6
and/or 5-HT7 receptor selective agents will shed light on the
physiological role of these interesting receptors.
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